Search | OpenScholar

Search results

1500 results found

Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29:1171-80.

Publication: Journal Article

Goldman, SM, F Kamel, GW Ross, SA Jewell, C Marras, JA Hoppin, DM Umbach, et al. 2014. “Peptidoglycan Recognition Protein Genes and Risk of Parkinson’s Disease. Mov Disord 2014;29:1171-80.”. Mov Disord.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13:767-76.

Publication: Journal Article

Hauser, RA, CW Olanow, KD Kieburtz, E Pourcher, A Docu-Axelerad, M Lew, O Kozyolkin, et al. 2014. “Tozadenant (SYN115) in Patients With Parkinson’s Disease Who Have Motor Fluctuations on Levodopa: A Phase 2b, Double-Blind, Randomised Trial. Lancet Neurol 2014;13:767-76.”. Lancet Neurol.

Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.

Publication: Journal Article

Bajaj, N, RA Hauser, J Seibyl, A Kupsch, M Plotkin, C Chen, and ID Grachev. 2014. “Association Between Hoehn and Yahr, Mini-Mental State Examination, Age, and Clinical Syndrome Predominance and Diagnostic Effectiveness of Ioflupane I 123 Injection (DaTSCAN™) in Subjects With Clinically Uncertain Parkinsonian Syndromes.”. Alzheimers Res Ther.

Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-6.

Publication: Journal Article

Goetz, CG, GT Stebbins, KA Chung, RA Hauser, JM Miyasaki, AP Nicholas, W Poewe, et al. 2013. “Which Dyskinesia Scale Best Detects Treatment Response? Mov Disord 2013;28:341-6.”. Mov Disord.

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 2017;89:1959-1969.

Publication: Journal Article

Mollenhauer, B, CJ Caspell-Garcia, CS Coffey, P Taylor, LM Shaw, JQ Trojanowski, A Singleton, et al. 2017. “Longitudinal CSF Biomarkers in Patients With Early Parkinson Disease and Healthy Controls. Neurology 2017;89:1959-1969.”. Neurology.

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-56.

Publication: Journal Article

Hauser, RA, A Hsu, S Kell, AJ Espay, K Sethi, M Stacy, W Ondo, M O’Connell, and S Gupta. 2013. “Extended-Release Carbidopa-Levodopa (IPX066) Compared With Immediate-Release Carbidopa-Levodopa in Patients With Parkinson’s Disease and Motor Fluctuations: A Phase 3 Randomised, Double-Blind Trial. Lancet Neurol 2013;12:346-56.”. Lancet Neurol.

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18:370-6.

Publication: Journal Article

Rascol, O, J Bronzova, RA Hauser, AE Lang, C Sampaio, A Theeuwes, and SV Van De Witte. 2012. “Pardoprunox As Adjunct Therapy to Levodopa in Patients With Parkinson’s Disease Experiencing Motor Fluctuations: Results of a Double-Blind, Randomized, Placebo-Controlled, Trial. Parkinsonism Relat Disord 2012;18:370-6.”. Parkinsonism Relat Disord.

Yarema Basil Bezchlibnyk

Person: Associate Professor

Dr. Bezchlibnyk's journey in medicine began with a Doctor of Medicine (MD) from the University of Toronto in 2010. Prior to this, he earned a PhD in Psychiatry from McMaster University in 2006. He completed his internship and residency in Neurosurgery at the University of Calgary Faculty of Medicine...

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

Publication: Journal Article

Hersh, BP, NL Earl, RA Hauser, and M Stacy. 2010. “Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson’s Disease Patients With Motor Fluctuations.”. Mov Disord.

Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.

Publication: Journal Article

Colosimo, C, P Martinez-Martin, G Fabbrini, RA Hauser, M Merello, J Miyasaki, W Poewe, et al. 2010. “Task Force Report on Scales to Assess Dyskinesia in Parkinson’s Disease: Critique and Recommendations.”. Mov Disord.